{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:11:06Z","timestamp":1730434266931,"version":"3.28.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fadolmidine, a novel selective \u03b1-adrenoceptor agonist, was evaluated for its efficacy to lower intraocular pressure in normotensive rabbits (n = 5\u20136). The dose-response profile between 0.004 \u03bcg and 12.5 \u03bcg of fadolmidine was determined. The effect of pH on the partition of fadolmidine was studied in order to select an optimal pH for topical fadolmidine administration. After topical administration, fadolmidine significantly lowered the intraocular pressure in normotensive rabbits. The onset of action was immediate, with no initial increase in intraocular pressure. A significant decrease in intraocular pressure was already observed at 1 h after dosing. The maximum decrease in intraocular pressure was observed after a 2.5 \u03bcg dose of fadolmidine in both eyes at 2 h after dosing. The mean maximum decrease in the treated and untreated eye was 6.4 mmHg and 3.9 mmHg, respectively. In conclusion, fadolmidine is a potent intraocular pressure lowering agent. In addition, fadolmidine does not cause a significant initial increase in intraocular pressure. Because of the strong dependence of the distribution coefficient on pH, the pH of the administered solution is important, with physiological pH being optimal in this respect.<\/jats:p>","DOI":"10.1211\/0022357055308","type":"journal-article","created":{"date-parts":[[2005,1,22]],"date-time":"2005-01-22T02:11:53Z","timestamp":1106359913000},"page":"191-195","source":"Crossref","is-referenced-by-count":2,"title":["Fadolmidine-induced ocular hypotension in normotensive rabbits"],"prefix":"10.1093","volume":"57","author":[{"given":"Jouko","family":"Savolainen","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Kuopio , PO Box 1627, FIN 70211, Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riku","family":"Niemi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Kuopio , PO Box 1627, FIN 70211, Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"M\u00e4ntyl\u00e4","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Kuopio , PO Box 1627, FIN 70211, Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhani","family":"Huuskonen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Kuopio , PO Box 1627, FIN 70211, Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomi","family":"J\u00e4rvinen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Kuopio , PO Box 1627, FIN 70211, Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,2,1]]},"reference":[{"key":"2024103109405079200_cit1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJM199810293391808","article-title":"Medical management of glaucoma","volume":"339","author":"Alward","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"2024103109405079200_cit2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/9783527614998.ch7","article-title":"Assessment of distribution-pH profiles","volume-title":"Lipophilicity in drug action and toxicology","author":"Avdeef","year":"1996"},{"key":"2024103109405079200_cit3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/02713688609015134","article-title":"Ocular effects of a relatively selective agonist (UK-14, 304\u201318) in cats, rabbits and monkeys","volume":"5","author":"Burke","year":"1986","journal-title":"Curr. Eye Res."},{"issue":"Suppl. 1","key":"2024103109405079200_cit4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0039-6257(96)82027-3","article-title":"Preclinical evaluation of brimonidine","volume":"41","author":"Burke","year":"1996","journal-title":"Surv. Ophthalmol."},{"key":"2024103109405079200_cit5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/00000542-199911000-00036","article-title":"Antinociceptive and hemodynamic effects of a novel-adrenergic agonist, MPV-2426, in sheep","volume":"91","author":"Eisenach","year":"1999","journal-title":"Anesthesiology"},{"key":"2024103109405079200_cit6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mpa.2001.117571","article-title":"Safety and efficacy of brimonidine in children with glaucoma","volume":"5","author":"Enyedi","year":"2001","journal-title":"J. AAPOS"},{"key":"2024103109405079200_cit7","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-349-16558-2","volume-title":"Physicochemical principles of pharmacy","author":"Florence","year":"1988"},{"key":"2024103109405079200_cit8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00061198-199708000-00010","article-title":"Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment","volume":"6","author":"Greenfield","year":"1997","journal-title":"J. Glaucoma"},{"key":"2024103109405079200_cit9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archopht.1977.04450080078007","article-title":"Clonidine: effects of a topically administered solution on intraocular pressure and blood pressure in open-angle glaucoma","volume":"95","author":"Harrison","year":"1977","journal-title":"Arch. Ophthalmol."},{"key":"2024103109405079200_cit10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00010-5","article-title":"Ocular absorption following topical delivery","volume":"16","author":"Jarvinen","year":"1995","journal-title":"Adv. Drug Del. Rev."},{"key":"2024103109405079200_cit11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/jop.2000.16.3","article-title":"The effectiveness and safety of brimonidine as mono, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial","volume":"16","author":"Lee","year":"2000","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"Suppl. 1","key":"2024103109405079200_cit12","first-page":"380","article-title":"MPV-2426, a novel alpha2-adrenergic agonist for spinal analgesia","volume":"59","author":"Lehtim\u00e4ki","year":"1999","journal-title":"Fundam. Clin. Pharmacol."},{"key":"2024103109405079200_cit13","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1097\/00000542-200006000-00034","article-title":"The mechanical antihyper-algesic effect of intrathecally administered MPV-2426, a novel -adrenoceptor agonist, in a rat model of post-operative pain","volume":"92","author":"Onttonen","year":"2000","journal-title":"Anesthesiology"},{"key":"2024103109405079200_cit14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0169-409X(95)00003-P","article-title":"Transport of small molecules through the blood-brain barrier: biology and methodology","volume":"15","author":"Pardridge","year":"1995","journal-title":"Adv. Drug Del. Rev."},{"key":"2024103109405079200_cit15","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/00000542-200004000-00027","article-title":"Attenuation of ascending nociceptive signals to the rostroventromedial medulla induced by a novel -adrenoceptor agonist, MPV-2426, following intrathecal application in neuropathic rats","volume":"92","author":"Pertovaara","year":"2000","journal-title":"Anesthesiology"},{"key":"2024103109405079200_cit16","first-page":"2799","article-title":"Medetomedine-induced alterations of intraocular pressure and contraction of the nictitating membrane","volume":"32","author":"Potter","year":"1991","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2024103109405079200_cit17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0378-5173(97)04907-7","article-title":"Potentiometric pKa determination of water-insoluble compounds: validation study in methanol\/water mixtures","volume":"151","author":"Takacs-Novak","year":"1997","journal-title":"Int. J. Pharm."},{"key":"2024103109405079200_cit18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0039-6257(93)90141-S","article-title":"Minimizing systemic absorption of topically administered opthalmic drugs","volume":"37","author":"Urtti","year":"1993","journal-title":"Surv. Ophthalmol."},{"key":"2024103109405079200_cit19","first-page":"2019","article-title":"Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures","volume":"33","author":"Vartiainen","year":"1992","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2024103109405079200_cit20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1034\/j.1399-6576.2000.440604.x","article-title":"The dissociation of sedative from spinal antinociceptive effects following administration of a novel alpha-2-adrenoceptor agonist, MPV-2426, in the locus coeruleus in the rat","volume":"44","author":"Xu","year":"2000","journal-title":"Acta Anaesthesiol. Scand."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F0022357055308","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/57\/2\/191\/60260810\/0022357055308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/57\/2\/191\/60260810\/0022357055308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:19:58Z","timestamp":1730369998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/57\/2\/191\/6147373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,2,1]]},"published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1211\/0022357055308","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2005,2]]},"published":{"date-parts":[[2005,2,1]]}}}